A shift towards larger CAG/CTG triplet repeats and schizophrenia (SCZ) and bipolar affective disorder (BPAD) has been detected by several recent studies, using the Repeat Expansion Detection (RED) technique, however no specific loci have been shown to be responsible for this shift. Further analyses by our group of RED (CTG) 10 ligation products amongst an extended sample of patients and comparison with controls matched for age, sex and ethnicity show no significant differences in distribution (P = 0.23, n = 95; P = 0.93, n = 91, for SCZ and BPAD respectively). Alleles at two recently discovered unstable trinucleotide repeat loci at 18q21.1 (SEF2-1B) and 17q21.3 (ERDA1) have also been analysed in affecteds and matched controls. We observed no increase in frequency of larger alleles (Ͼ Ͼ Ͼ37 repeats) in affected individuals at SEF2-1B (BPAD: P = 0.95, n = 100; SCZ: P = 0.61, n = 97) or at ERDA1 (BPAD: P = 0.4, n = 101; SCZ: P = 0.05, n = 151, with larger alleles more frequent in controls). Our findings suggest that larger CAG/CTG repeats at these loci are neither major contributory factors to the etiology of psychosis, nor in linkage disequilibrium with a gene that is. Furthermore, when the RED results were compared to allele sizes at SEF2-1B and ERDA1, it was observed that a majority of SCZ, BPAD and control individuals with large RED products had a large allele at either or both sites (78% for RED products у у у270 bp; 62% for RED products у у у180 bp).
Introduction
The genetic basis of the etiologies of both schizophrenia (SCZ) and bipolar affective disorder (BPAD) has been considered for many decades, with twin, family, and adoption studies indicating that the familial clustering of affected individuals is accounted for largely by genetic factors. Despite strong evidence for an hereditary component to SCZ and BPAD, very little is understood about the underlying etiopathogenic mechanisms. In the wake of the discovery of unstable DNA as a molecular basis for genetic anticipation in such diseases as Huntington's disease (HD), myotonic dystrophy (DM) and many others, and the recently rediscovered, albeit still controversial, evidence for genetic anticipation in major psychoses, the genetic epidemiology can be re-evaluated to demonstrate support for the unstable DNA model. 1 Many of the non-Mendelian aspects of the inheritance of SCZ and BPAD Correspondence: Dr JL Kennedy, R-31, Neurogenetics Section, Clarke Division, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada. E-mail: kennedyjȰcs.clarke-inst.on.ca Received 25 August 1998; revised 28 October 1998; accepted 2 November 1998 could be explained by the behaviour of unstable DNA, 1, 2 and several molecular genetic approaches are available for testing the hypothesis. [3] [4] [5] Initial studies in major psychosis investigating trinucleotide repeats have shown encouraging results. [6] [7] [8] [9] [10] [11] Other data, however, would suggest that the occurrence of unstable DNA in both SCZ and BPAD may be less prevalent or of a more subtle nature than previously thought. [12] [13] [14] [15] [16] Attempts to identify specific CAG/CTG repeat loci responsible for the observed shift towards larger repeats in affecteds observed in several studies have so far been unsuccessful. [17] [18] [19] [20] [21] A large, unstable repeat identified in a Danish SCZ pedigree 22 and localized to chromosome 18 10 has recently been cloned, sequenced and characterised. 23 This CTG repeat occurs in an intron of the gene encoding the transcription factor SEF2-1B. Alleles of intermediate size at this repeat (53-200× CTG) occur fairly frequently in affected and control populations, and large 'super' alleles (Ͼ800× CTG) occur much less frequently. Neither size-range of large alleles appears to co-segregate with major psychosis. 22, 23 A second large repeat, ERDA1, 24, 25 localizes to 17q21.3 and appears to have a high frequency of large alleles in the normal population. This repeat appears to demonstrate instability, and evidence of expansion above the range seen in the normal popu-lation has been reported in a family with childhood onset depression. 26 The repeats at SEF2-1B and ERDA1 are thought to be responsible for the majority of large RED products observed. 27 In this study we have attempted firstly to strengthen our genome-wide analysis of CAG/CTG repeats in SCZ and BPAD populations vs matched controls using RED as reported previously 12 by increasing the sample size, and secondly to investigate the specific CAG/CTG repeats at the SEF2-1B and ERDA1 loci in affected vs control populations. ). All sample subjects were classified as having BPAD type I (ie occurrence of manic episodes severe enough to cause hospitalization or major impairment of function). SCZ patients were recruited from the Psychopharmacology Clinic at Case Western Reserve University in Cleveland, Ohio, as well as Hillside Hospital, Long Island, New York, and patients were diagnosed according to DSM-III-R criteria, as derived from SADS-L structured interview. Scores at baseline for the Brief Psychiatric Rating Scale (BPRS), also for subscales of the BPRS for positive and negative symptoms (BPOS and BNEG respectively) and for Global Assessment Scale (GAS) were obtained for a subset of 46 SCZ patients. Blood was taken after obtaining informed consent, and DNA was extracted from lymphocytes using standard salting out procedure. The control DNA samples were obtained from staff members at the Clarke Institute and Case Western Reserve University and members of the public responding to advertisements who had been assessed for absence of psychiatric illness using the screening questions from the SCID interview (DSM-IV). Details of ethnic background (including place of birth, language and religion of patients and their parents) were obtained from patients to ascertain pre-immigration ethnic roots, and controls were matched pairwise (and thus patient and control numbers are equal) as closely as possible to reflect this. Patients and controls were also matched pairwise for age (± 5 years) and gender. Mean age for BPAD was 39.0 ± 10.7 years, and for the matched controls 38.0 ± 10.2 years. Fifty-seven per cent were female and 43% were male. Mean age for SCZ was 34.2 ± 8.5 years, and for the matched controls 33.3 ± 8.3 years. Twenty-eight per cent were female and 72% were male. The overall ethnic breakdown of the groups was as follows: SCZ (and matched controls) 82% Caucasian, 17% black, 1% oriental; BPAD (and matched controls) 95% Caucasian, 4% native Canadian/Metis, 1% oriental and 0% black.
Materials and methods

Sample
Repeat expansion detection (RED)
analysis RED was performed as described by Schalling et al, 3 with modifications, 12 using approximately 5 g of genomic DNA and 100 ng of the phosphorylated oligonucleotide (CTG) 10 . DNAs from two myotonic dystrophy individuals with large CAG repeats were used as positive controls. The patient samples included the 52 BPAD and 54 SCZ patients reported in our previous study. 12 Genotyping at SEF2-1B and ERDA1 SCZ and BPAD individuals and matched controls were genotyped for SEF2-1B and ERDA1 using PCR as described by Breschel et al 23 and Nakamoto et al, 24 and the PCR product then underwent electrophoresis on 6% denaturing polyacrylamide gels. DNA was transferred by blotting to Hybond-N + (Amersham Canada, Oakville, ON, Canada) membranes, and hybridized with a 3Ј-end labelled (CAG) 10 probe. The Sequamark (Research Genetics, Huntsville, AL, USA) sequencing ladder was used to size alleles. Southern hybridization analysis, using EcoRI (SEF2-1B) or HindIII (ERDA1) digested genomic DNA and DNA probes flanking the repeat regions, was used to confirm the presence of large alleles (Ͼ37 repeats), or the lack of large alleles for individuals who are apparently homozygotes with normal alleles.
Statistical analyses RED products were scored and compared across affected and control groups using the Mann-Whitney (M-W) rank test, and for corroboration, with a Wilcoxon test for paired samples. SEF2-1B and ERDA1 allele frequencies were also compared for affected and control groups using the M-W test. Large alleles (those with 50 or more repeats) were grouped together. Spearman's test was used to look for correlation between RED product size or larger allele size vs age, or age of illness onset, and for a subset of SCZ individuals, for severity scores. The non-parametric M-W, Wilcoxon-pair and Spearman's tests were used because the distribution of RED products and alleles in the population is nonnormal. All P-values shown are two-tailed. Using a simplified assumption to calculate the possible power of the sample, eg splitting the alleles into a dichotomous distribution with a repeat size of 37 and above, we estimate the association analyses have 80% power to detect an allelic effect size of 0.22 (n = 151) to 0.26 (n = 100) assuming ␣ = 0.05.
Results
RED
The RED product frequencies for both SCZ and BPAD and their matched controls are shown in Figure 1a and b respectively. Comparison of RED product sizes for affecteds and controls using the M-W test gave P = 0.23 for SCZ (U = 4072, n = 95) and P = 0.93 for BPAD (U = 411, n = 91). The Wilcoxon test for paired samples gave P = 0.32 (Z = −0.98) and P = 0.98 (Z = −0.019) for SCZ and BPAD respectively. The samples were split and analysed for both genders separately using M-W to determine whether a sex effect was present, as has been reported in several previous studies. 9, 29 No significant differences in distribution were seen between male affecteds and matched controls, female affecteds and matched controls, male vs female affecteds or male vs female controls (P Ͼ 0.05). No significant correlations were observed with age or age-of-onset. RED product size showed negative correlation with BPRS (n = 46, Spearman's coefficient = −0.30, P = 0.047) and BPOS (n = 46, Spearman's coefficient = −0.36, P = 0.014) scores, which were non-significant after accounting for multiple testing.
SEF2-1B
The allele frequencies for SEF2-1B for both SCZ and BPAD and their matched controls are shown in Figure  2a and b respectively. The presence of all large alleles was confirmed by Southern hybridization to EcoRIdigested genomic DNA. Lack of large alleles was also confirmed by this approach for individuals who exhibited apparent homozygosity for smaller alleles using the PCR-based approach. Bias against amplification of large alleles could otherwise lead to an over-representation of the smaller alleles. No 'super' alleles (Ͼ800 repeats) were detected, and no somatic mosaicism was apparent in lymphocytes from any affected or control individuals, using the genomic Southern approach. Comparison of allele sizes for affected and control populations showed no significant differences in distribution of alleles, and no increase of expanded alleles amongst affecteds vs controls (SCZ: M-W, U = 18361, P = 0.61, n = 97; BPAD: M-W, U = 19930, P = 0.95, n = 100). As with the RED analyses, no significant differences in distribution were seen between any of the gender-specific subgroups. No significant correlations were observed for larger allele size and either age, ageof-onset, BPRS, BPOS, BNEG or GAS scores.
ERDA1
Allele frequencies for ERDA1 for both SCZ and BPAD and their matched controls are shown in Figure 3a and b respectively. The presence or lack of large alleles was confirmed by Southern hybridization to HindIIIdigested genomic DNA using probe pSKERDA1. No somatic mosaicism was apparent in any affected or control individuals, using the genomic Southern approach. Comparison of allele sizes for affected and control populations showed no significant differences in distribution of alleles, and no increase of large alleles amongst affecteds vs controls (SCZ: M-W, U = 41485, P = 0.05, n = 151, larger alleles more frequent in control group; BPAD: M-W, U = 19529, P = 0.40, n = 101). As with the RED and SEF2-1B analy- ses, no significant differences in distribution were seen between any of the gender-specific subgroups. A positive correlation of larger allele size for ERDA1 with ageof-onset for BPAD was marginally significant (Spearman's coefficient = 0.26, n = 77, P = 0.022). No significant correlations were observed for larger allele size and either age, BPRS, BPOS, BNEG or GAS scores.
For individuals with RED products 180 bp or larger, 58% of BPAD individuals (n = 45) had large alleles (у50 repeats) at ERDA1, 20% at SEF2-1B, 69% at either ERDA1 or SEF2-1B, and 9% at both sites. For SCZ (n = 43), 33% had large alleles at ERDA1, 12% at SEF2-1B, 42% at either and 2% at both. For control individuals with RED products у180 bp (n = 67), 57% had large alleles at ERDA1, 13% at SEF2-1B, 70% at either site, and 0% at both. However, none of these results achieved statistical significance. Ethnic background of individuals with large SEF2-1B and ERDA1 alleles was in proportion to the distribution of ethnic groups in the sample, and no evidence was seen of large repeats clustered in any sub-ethnic groups.
Discussion
It would be naive to expect an unstable trinucleotide gene to be a major gene for either SCZ or BPAD, as neither disease is expected to be caused by a single major gene. Given the high frequencies of large alleles at SEF2-1B and ERDA1 in our affected and control populations as well as others, [23] [24] [25] 27 such high frequencies are likely the case in other studies which have reported significant increases in CAG/CTG repeat distribution amongst affected individuals. [6] [7] [8] [9] 11, 29 A recently published study has reported weak evidence of association of large repeats at SEF2-1B (but not ERDA1) with BPAD. 30 Our findings in this study contradict this. The lack of evidence of larger repeats in affected populations for either repeat in the present study is consistent with our findings for RED. The lack of differences in distribution of CAG/CTG genomewide and at SEF2-1B and ERDA1 in our study may reflect the close, pairwise matching of affected and control individuals for ethnic background including pre-immigration roots.
Although previous studies observed a significant effect for female schizophrenics only 9 and for male childhood-onset schizophrenics, 28 no evidence of a sex effect was observed in this study. However, for the unstable DNA hypothesis, it is a sex-of-transmittingparent effect rather than a sex effect within the offspring that is expected. Since in the vast majority of cases parental DNA was not available, it was not possible to test the hypothesis of parental effect.
In view of previous studies demonstrating earlier age-of-onset for individuals with larger repeats, 8, 9 consistent with the unstable DNA hypothesis, we looked for evidence of correlation of increased severity and/or earlier age-of-onset with larger repeats in our affected populations. Negative correlations were observed for RED and the BPRS and BPOS measures of disease severity for SCZ, showing larger CAG/CTG repeats in individuals with lower severity measures, and thus contradicting the hypothesis. Age-of-onset and ERDA1 allele size also showed a modest positive correlation, also contradicting the hypothesis. All correlations, when adjusted for multiple testing, were non-significant.
It is possible, however, that an unstable repeat gene may be responsible for a small subset of psychosis. No significant increases of larger repeat alleles were found for SEF2-1B or ERDA1 in either SCZ or BPAD in our sample populations. We have previously identified an intergenerational expansion at ERDA1 from a mildly affected father to a daughter severely affected with childhood onset depression, 26 with larger alleles (115 repeats) than any previously reported 24, 25, 27 or observed in our population samples. The evidence presented in this study, however, suggests that neither SEF2-1B nor ERDA1, at least for repeats within the size range observed in our affected and control populations, are pathogenic in major psychosis, and thus it is necessary to search for and study other potentially diseaseassociated repeats. It is also likely that there are other 'innocent' unstable repeats in the genome (the RED-1 locus which was mapped by linkage to 18q 3 may be one such repeat). Thus a combination of studies of pedigrees to look for co-segregation of large repeat alleles with the disease, studies to assess the transmission of the large alleles to offspring in triads and characterization and analysis of adjacent coding regions (if any), will successfully elucidate any etiological role for these repeats. One interesting, albeit not statistically significant, observation is that 9% of BPAD individuals with large (у180 bp) RED products have large (у50 repeats) alleles for both SEF2-1B and ERDA1, compared to 2% of SCZ and none of the control individuals. An epistatic model of predisposition to BPAD cannot be excluded.
The RED method has been unable to prove or disprove a role for CAG/CTG repeats in SCZ and BPAD, partly because of: (a) probable genetic heterogeneity in affected populations; (b) the high background of 'innocent' large repeats such as SEF2-1B and ERDA1 in the population; and (c) the lack of sensitivity of the technique to discern smaller, potentially disease-causing repeats which may be masked by the high level of background repeat DNA. However, it remains a useful method for screening for individuals containing very large stretches of repeats. After removing all large RED products thought to be due to SEF2-1B and ERDA1, the remainder represents a highly enriched sample of individuals with CAG/CTG repeats within the pathogenic size-range of other trinucleotide repeat diseases, but at unknown, possibly etiologic sites. The localization and characterization of these repeats for SCZ and BPAD will hopefully clarify the recent speculation regarding unstable DNA, anticipation and major psychosis.
